Tonghua Dongbao Pharmaceutical Management
Management criteria checks 3/4
Tonghua Dongbao Pharmaceutical's CEO is Chun Sheng Leng, appointed in May 2020, has a tenure of 11.17 years. directly owns 0.12% of the company’s shares, worth CN¥17.50M. The average tenure of the management team and the board of directors is 5 years and 5 years respectively.
Key information
Chun Sheng Leng
Chief executive officer
CN¥3.7m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 5yrs |
| CEO ownership | 0.1% |
| Management average tenure | 5yrs |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
CEO
Chun Sheng Leng (50 yo)
Mr. Chun Sheng Leng serves as a Director and General Manager since Mach 27, 2024 and served as the Chairman and General Manager at Tonghua Dongbao Pharmaceutical Co., Ltd. since May 7, 2020 until March 27,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 5yrs | CN¥3.73m | 0.12% CN¥ 17.5m | |
| Chief Accountant | 5yrs | CN¥852.40k | no data | |
| Deputy GM & Director | 5yrs | CN¥1.17m | 0.014% CN¥ 2.0m | |
| Deputy GM & Director | 5yrs | CN¥1.17m | 0.031% CN¥ 4.6m | |
| Board Secretary | 4.9yrs | CN¥992.50k | no data |
Experienced Management: 600867's management team is seasoned and experienced (5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 11.2yrs | CN¥3.73m | 0.12% CN¥ 17.5m | |
| Deputy GM & Director | 5yrs | CN¥1.17m | 0.014% CN¥ 2.0m | |
| Deputy GM & Director | 5yrs | CN¥1.17m | 0.031% CN¥ 4.6m | |
| Chairman of the Supervisory Board | 4.7yrs | CN¥1.17m | 0.14% CN¥ 21.5m | |
| Supervisor | 5yrs | CN¥173.20k | no data | |
| Director | 4.7yrs | no data | no data | |
| Employee Representative Supervisor | 5yrs | no data | no data | |
| Chairman of the Board | 5yrs | CN¥173.20k | 0.27% CN¥ 40.5m | |
| Independent Director | 9.8yrs | CN¥100.00k | no data | |
| Independent Director | 3yrs | CN¥100.00k | no data | |
| Independent Director | 3yrs | CN¥100.00k | no data | |
| Director | 1.7yrs | no data | no data |
Experienced Board: 600867's board of directors are considered experienced (5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/21 09:25 |
| End of Day Share Price | 2025/05/21 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tonghua Dongbao Pharmaceutical Co., Ltd. is covered by 28 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kan Li | Chasing Securities |
| Yanyin Zhu | China International Capital Corporation Limited |
| Bing Zhao | China Renaissance Securities |